MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$285,663
Unit: Dollar
Positive Cash Flow Breakdown
Accounts payable and accrued exp...
Accounts payable and accrued exp...
Proceeds from stock sales
Others
Negative Cash Flow Breakdown
Net income (loss) attributable t...
Change in fv of derivative
Investment in intangibles
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Debt discount amortization, incl. issuance of warrants
-
-
0
-
Interest paid for note conversion
-
-
0
-
Gain/loss of issuance
-
-
0
-
Acquisition of subsidiary
-
-
0
-
Acquisition of subsidiary, affiliates
-
-
0
-
Net loss
-
-2,068,989
-522,155
-282,725
Net income (loss) attributable to bioxytran
-2,688,918
-
-
-
Amortization of ip
5,580
2,108
2,948
4,236
Stock-based compensation
30,515
35,838
63,645
65,487
Stock-based compensation affiliates
0
1,278,600
53,946
125,547
Change in fv of derivative
106,759
-73,136
15,853
264,796
Debt forgivness
-
-
-133,867
-
Change in pre-paid expenses
0
-3,551
3,551
-
Accounts payable and accrued expenses
133,181
215,868
-199,257
72,985
Accounts payable and accrued expenses affiliates
207,639
221,278
517,173
115,014
Net cash used in operating activities
-349,773
-238,610
-236,971
-41,474
Investment in intangibles
9,383
9,227
6,240
1,674
Net cash used in investing activities
-9,383
-9,227
-6,240
-1,674
Proceeds from note sales
-
-
0
-
Stock subscription for cash
-
-
-
13,353
Proceeds from stock sales
45,346
145,701
438,986
-
Short-term loans
-
-
10,000
2,000
Proceeds from warrant issuance
28,147
95,339
292,230
-
Short-term loans from affiliates
0
-40,070
10,763
300,327
Net cash provided by financing activities
73,493
200,970
738,626
54,503
Net increase (decrease) in cash
-
-
495,415
-
Net decrease in cash
-285,663
-46,867
495,415
11,355
Cash, beginning of period
463,047
509,914
14,499
5,154
Cash, end of period
177,384
463,047
509,914
14,499
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from stock sales
$45,346
Proceeds from warrant
issuance
$28,147
Net cash provided by
financing activities
$73,493
(-71.86%↓ Y/Y)
Net decrease in cash
-$285,663
(-14112.09%↓ Y/Y)
Canceled cashflow
$73,493
something is missing
$2,068,989
Accounts payable and
accrued expenses...
$207,639
(258.16%↑ Y/Y)
Accounts payable and
accrued expenses
$133,181
(-78.59%↓ Y/Y)
Stock-based compensation
$30,515
(-26.05%↓ Y/Y)
Amortization of ip
$5,580
(27.98%↑ Y/Y)
Net cash used in
operating activities
-$349,773
(-41.03%↓ Y/Y)
Canceled cashflow
$2,445,904
Net cash used in
investing activities
-$9,383
(38.18%↑ Y/Y)
Net income (loss)
attributable to bioxytran
-$2,688,918
Change in fv of
derivative
$106,759
(121.47%↑ Y/Y)
Investment in intangibles
$9,383
(-38.18%↓ Y/Y)
Buy us a coffee
BIOXYTRAN, INC (BIXT)
BIOXYTRAN, INC (BIXT)